BioRem Inc.

Total Valuation

BioRem Inc. carries a market capitalization of 35.23M, placing it among publicly traded companies globally. Its enterprise value stands at 32.04M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

BioRem Inc. currently has 16.13M shares outstanding.

Valuation Ratios

BioRem Inc. trades at a trailing price-to-earnings ratio of 7.91. The price-to-sales ratio is 0.89, and the price-to-book ratio stands at 3.50.

Enterprise Valuation

On an enterprise value basis, BioRem Inc. trades at an EV/EBITDA multiple of 4.50 and an EV/FCF ratio of 12.92. The EV/Sales ratio of 0.72 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 4.79 provides insight into valuation relative to core operating earnings.

Financial Position

BioRem Inc. maintains a current ratio of 2.02, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 17.32, indicating elevated leverage, while an interest coverage ratio of 46.22 demonstrates strong ability to service its debt obligations.

Financial Efficiency

BioRem Inc. posts a return on equity of 56.53 and a return on invested capital of 30.06.

Taxes

Over the trailing twelve months, BioRem Inc. has paid 1.57M in income taxes, reflecting an effective tax rate of 23.96.

Stock Price Statistics

BioRem Inc.'s stock has gained approximately 33.95062% over the past 52 weeks. The 50-day moving average sits at 2.24, while the 200-day moving average is 1.94.

Income Statement

Over the trailing twelve months, BioRem Inc. generated 44.44M in revenue and converted that into 4.98M in net income, yielding earnings per share of 0.27. EBITDA reached 7.11M, while operating income came in at 6.69M.

Balance Sheet

BioRem Inc. holds 9.99M in cash and equivalents against 2.65M in total debt, resulting in a net debt position of -8.28M. Total book value stands at 11.26M, with working capital of 14.51M providing operational flexibility.

Cash Flow

BioRem Inc. produced 1.81M in operating cash flow over the past twelve months. After subtracting -548,337.00 in capital expenditures, free cash flow totaled 1.27M - equivalent to 0.08 per share.

Margins

BioRem Inc. operates with a gross margin of 29.36, reflecting its pricing power and cost economics. The operating margin of 15.05 and net profit margin of 11.21 provide insight into operational efficiency.

Dividends & Yields

Scores

BioRem Inc. posts an Altman Z-Score of 4.38, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.